Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast …
WEBDec 5, 2018 · The ExteNET trial evaluated 1 year of extended adjuvant therapy with neratinib monotherapy as compared with placebo after completion of 1 year of trastuzumab. 17 In the APHINITY trial, patients ...
Adjuvant T-DM1 versus trastuzumab in patients with residual …
WEBBackground: In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab.Here, we present additional exploratory safety and efficacy analyses.
T-DM1 Approval Expanded for HER2-Positive Breast Cancer
WEBMay 23, 2019 · Ado-trastuzumab, also called T-DM1, was initially approved by FDA more than 6 years ago to treat women with metastatic HER2-positive breast cancer. Under the expanded approval, it can now be used when the cancer is far less advanced: as a post-surgical, or adjuvant, treatment in women with early-stage HER2-positive breast cancer.
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
WEBNov 8, 2012 · Phase 2 studies have shown the clinical activity of T-DM1 in patients with HER2-positive advanced breast cancer. 9–11. The EMILIA study, a phase 3 trial, assessed the efficacy and safety of T ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to …
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2 ... - PubMed
WEBIntroduction: The prognosis of patients with HER2-positive early breast cancer has radically improved after the introduction of (neo)adjuvant anti-HER2 targeted therapy.Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining the anticancer properties of the anti-HER2 agent trastuzumab and the antineoplastic cytotoxic drug DM1.
Adjuvant trastuzumab emtansine in HER2-positive breast cancer …
WEBSep 19, 2022 · Denkert, C. et al. Biomarker data from KATHERINE: a phase 3 study of adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for ...
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant …
WEBFeb 26, 2021 · Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate of trastuzumab [a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)] and DM1 (an inhibitor of tubulin polymerisation). It was initially approved in the European Union for the treatment of adult patients with HER2-positive unresectable locally advanced or metastatic breast cancer (BC) who had previously ...
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant …
WEBA phase III randomised, multicentre, open-label trial compared T-DM1 with trastuzumab as adjuvant therapy in patients with HER2-positive early BC who had received preoperative chemotherapy and HER2-targeted therapy followed by surgery, with a finding of invasive residual disease in the breast and/or axillary lymph nodes. The study met its ...
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast …
WEBMar 23, 2022 · Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload ...